Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GA
Galectin Therapeutics Inc.
GALT
Mkt Cap
$366.0M
Volume
144.57K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GA
GALT
GA
Galectin Therapeutics Inc.
GALT
News
·
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Mkt Cap
$365.1M
Volume
144.57K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Galectin Therapeutics presented new data from its NAVIGATE trial at EASL 2026 showing that belapectin 2 mg/kg demonstrated statistically significant reduction in new varices development at 18 months (p=0.04) and improvements in liver stiffness in patients with advanced MASH cirrhosis. The poster presentation on portal hypertension risk reduction was designated a TOP Poster at the conference. These findings support belapectin's potential as a disease-modifying therapy, with no currently approved alternatives available for this indication.
GlobeNewswire Inc. · May 27, 2026
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
Galectin Therapeutics reported Q3 2025 financial results, highlighting promising biomarker data from the NAVIGATE trial for belapectin in treating MASH cirrhosis. The company submitted data to the FDA and is seeking guidance on next steps, with encouraging results showing potential disease progression reduction.
GlobeNewswire Inc. · Nov 14, 2025
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
Galectin Therapeutics is hosting a virtual event to discuss its drug belapectin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. The event will feature key opinion leaders and highlight results from the company's NAVIGATE Phase 3 clinical trial.
GlobeNewswire Inc. · Jun 10, 2025
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
Galectin Therapeutics announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented at the 2025 MASH-TAG Conference. The company's executive leadership will also host one-on-one meetings during the JP Morgan Healthcare Conference to discuss the NAVIGATE topline results and the next steps for the belapectin program.
GlobeNewswire Inc. · Jan 10, 2025
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
Galectin Therapeutics reported financial results for Q2 2024, with a net loss of $12.4 million. The company's lead drug, belapectin, is in a Phase 2b/3 trial for the treatment of MASH-related liver cirrhosis, with interim data expected in December 2024.
GlobeNewswire Inc. · Aug 13, 2024
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy.
GlobeNewswire Inc. · Jun 4, 2024
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024.
GlobeNewswire Inc. · May 15, 2024
Wall Street Breakfast: The Week Ahead
Geopolitical tensions in the Middle East, earnings reports from major companies, and the upcoming bitcoin halving event are set to drive market focus this...
Seeking Alpha · Apr 14, 2024
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.
GlobeNewswire Inc. · Mar 29, 2024
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
The Motley Fool · Mar 17, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
GA
GALT
Galectin Therapeutics Inc.
Buy
Sell
Market
Limit
Soon
GALT
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any GALT yet.
Related Tickers
Earnings